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Abstract. 
 
 
Background: The diagnostic value added by musculoskeletal ultrasound (MSUS) over standard 
clinical and laboratory parameters has proved difficult to quantify. The additive contribution to 
diagnostic classification of a pragmatic, 15 minute MSUS protocol was appraised in a large, 
unselected cohort of early arthritis clinic attendees. 
Methods: Detailed baseline characteristics were recorded. Semi-quantitative MSUS scoring of the 
most symptomatic wrist, 2nd/3rd MCPs and PIPs and 2nd/5th MTPs was recorded, along with the 
sonographer’s scan impression (“definitely inflammatory,” “possibly inflammatory” or “non-
inflammatory”). MSUS findings were available to rheumatologist diagnosticians during subsequent 
consultations. Persistent inflammatory arthritis (PIA) was classified only where patients were started 
on >1 disease modifying anti-rheumatic drug (DMARD). Multivariate and ROC curve analyses were 
used to identify independent discriminators of PIA, and the added value of MSUS parameters.  
Results: 831 patients were enrolled, of whom 31.3% acquired a PIA diagnosis. SJC, CRP, age and 
ACPA status were non-redundant clinical/laboratory predictors of a PIA diagnosis by consulting 
rheumatologists, with good discriminatory utility (AU ROC 0.88). While the additive contribution of 
summed parameters from the 7-joint MSUS protocol to this model was statistically significant 
(p=0.004) it was numerically small (AU ROC 0.02). However, the additive contribution to diagnostic 
outcome of “sonographer’s scan impression” over clinical parameters alone became substantial in 
the sub-cohort of ACPA-negative patients, increasing the AU ROC by 9% from 0.81 to 0.90 (p<.0001). 
Conclusions: The clinical utility of a 15-minute MSUS screen for diagnosing PIA requiring DMARDs is 
most evident amongst ACPA negative patients attending an EA clinic. 
  
The importance of prompt therapeutic intervention to improve outcomes for immune-mediated 
inflammatory arthritis [1] explains the recent growth in early arthritis clinics. Ever-earlier evaluation 
of patients with suspected inflammatory arthritis (SIA) poses new challenges to rheumatologists, not 
least when assessing synovitis which may remain subtle or sub-clinical in early disease. 
Musculoskeletal ultrasound (MSUS) is a potentially valuable tool in this context, having greater 
sensitivity for detecting abnormalities than clinical examination alone[2]. Expert consensus supports 
its use, but there is a paucity of real-world data on its value in busy clinical settings[3, 4]. 
Several outstanding issues warrant consideration. First, defining a sub-group of SIA patients for 
whom prioritised MSUS access maximally impacts clinical decision-making could significantly 
streamline service delivery. Here, the presence of MSUS abnormalities in the peripheral joints of 
autoantibody seropositive arthralgia patients who lack clinical synovitis has been shown to predict 
arthritis persistence[5]; limited data also indicate that power Doppler signal may increase the 
likelihood of persistent joint inflammation in an autoantibody seronegative group of patients with 
hand arthralgia and early morning stiffness[6]. Second, defining a “minimum MSUS dataset” that can 
rapidly be acquired for such patients is needed. Considering this in patients with early, clinically-
detectable synovitis, Filer et al showed that summed power Doppler scores from 10 out of a total of 
38 peripheral joints improved predictive value for the development of rheumatoid arthritis over 
clinical variables alone[7]. Whether such findings may be extrapolated for predicting persistent 
arthritis development in unselected SIA patients is unknown, although algorithms ignoring the wrists 
are unlikely to be informative[8]. Finally, the healthcare professional(s) best-placed to deliver MSUS 
assessments, and the format via which their findings are best reported to non-scanning 
diagnosticians, are often overlooked.  
An evidence-based strategy for applying MSUS in the routine assessment of newly-referred SIA 
patients remains a pressing unmet need. In addition to studies of the kind referred to above 
(reviewed in Reference [3]), real-world data from large, unselected early SIA populations are likely to 
inform their development. A published 7-joint ultrasound protocol[9] has been adapted for 
pragmatic application during 15-minute screening appointments that form part of all initial patient 
assessments in the Newcastle Early Arthritis Clinic (NEAC) since 2012. We determined that 
quantifying the additive contribution of MSUS to clinicians’ diagnostic behaviour over and above 
clinical and laboratory parameters alone might (i) appraise the utility of our clinical strategy, and (ii) 
point towards a definable subgroup of SIA patients attending the clinic for whom such a strategy 
might be prioritised. 
  
Methods. 
For a full description of methods see on-line Supplementary Information. 
Patients and clinical procedures. Consecutive treatment-naïve adults referred from primary care 
with SIA to the NEAC between January 2015 and August 2017 were enrolled. Such patients receive 
two initial assessment appointments one week apart. At the first, detailed baseline demographic and 
clinical parameters are undertaken, along with MSUS assessment. At the subsequent visit, patients 
are reviewed by a consultant rheumatologist with access to all results, and assigned an initial clinical 
diagnosis. We considered a diagnosis of ‘persistent inflammatory arthritis’ (PIA), warranting 
commencement of ≥1 disease modifying anti-rheumatic drug(s), as the most clinically relevant 
outcome. Supplementary Figure S1A summarises the clinical pathway within which data were 
collected.   
MSUS Assessment. Images recording longitudinal dorsal views of the wrist, 2nd and 3rd MCPs, 2nd and 
3rd PIPs and 2nd and 5th MTPs of the most symptomatic hand/foot were mandated in all patients, 
based on the Backhaus protocol[9].  Imaging of additional joint areas was permitted at the 
sonographer's discretion according to individual patient symptoms, but with maximum 
scanning/recoding time of 15 minutes per patient. MSUS findings were recorded on a semi-
quantitative (0-3) scale for greyscale (GS) and power Doppler (PD) domains according to consensus 
definitions[10, 11]. 7-joint GS and PD “synovitis load” was calculated for each patient as described in 
Supplementary Information. Relevant findings at non-mandated joint areas were noted as free-text. 
Finally, sonographers recorded their “scan impression”, a global interpretation of mandated and 
non-mandated scan findings in relation to the presence of inflammatory arthritis (definite, possible, 
absent; scored 0, 1, 2, respectively). All findings were documented (Supplementary Figure S1B). 
Data management and analysis. All analyses were carried out using JMP Pro 13.0 (SAS Institute Inc) 
using methods previously outlined[8]. Multivariate and ROC curve analyses were used to identify 
independent discriminators of PIA, and the added value of MSUS parameters.
Results. 
Patients. 831 consenting patients, enrolled between January 2015 and August 2017, were followed 
up for a minimum of 6 months (median 15 months) during the study. The evolution of clinical 
diagnoses as assigned by consulting rheumatologists is summarised in Supplementary Table S1 and 
Supplementary Figure S1C. Amongst PIA patients, DMARDs were commenced at the first consultant 
visit in the majority (75%) of cases, the remainder being commenced during follow-up. Baseline 
clinical, serological and MSUS characteristics of all patients are compared in Table 1 according to 
whether they were or were not assigned a diagnosis of PIA.  
Clinical and laboratory predictors of PIA. To identify clinical and laboratory parameters that had 
independent predictive value with respect to diagnostic outcome in the complete cohort, all 13 of 
the non-MSUS variables listed in Table 1 were entered into a backward stepwise logistic regression 
analysis. Four non-redundant variables were independently associated with PIA: ACPA status, SJC, 
CRP and age. The final model containing these predictors was significantly associated with outcome 
(χ2 [4 degrees of freedom] = 372.01; P<.0001). The strong discriminatory utility of ACPA 
autoantibody status for PIA was expected given its established positive predictive value for RA in 
early arthritis clinics[12, 13]. Indeed, we and others have highlighted the peculiar challenge of 
diagnosing seronegative SIA in this setting[14-16]. Mindful of the potential additive value of MSUS 
for this specific purpose [6], we stratified our cohort accordingly, repeating regression analysis in the 
ACPA-negative sub-cohort (n=703) amongst whom a significantly lower proportion of patients 
developed PIA during the follow-up period (20.8%, versus 89.1%; p=<.0001). Here, only three non-
redundant variables (SJC, CRP and age) emerged as independent predictors of PIA, the resultant 
model also being associated with outcome (χ2 [3 degrees of freedom] = 168.0; P<.0001). Results of 
these multivariable analyses are presented in Supplementary Table S2. 
Additive contribution of MSUS parameters to diagnostic outcome. “Synovitis load” and “scan 
impression” (see Methods) were considered separately as alternate means by which MSUS 
assessment could add independent diagnostic information. In the overall cohort and ACPA-
seronegative sub-cohort, both synovitis load and scan impression demonstrated an additive 
predictive value for PIA outcome independently of clinical parameters (Supplementary Tables S3 and 
S4). A range of cut-offs for a “risk metric” generated from each predictive model could then be used 
to plot paired ROC curves depicting the discriminatory utility of clinical parameters alone versus 
clinical + MSUS parameters with respect to the PIA outcome of interest[17]. Using this approach, 
clinical/laboratory parameters alone exhibited a good discriminatory ability for a diagnostic outcome 
of PIA in the complete cohort, with an area under (AU) ROC of 0.88 (95% CI =0.85-0.91). By 
incorporating “synovitis load” into the model there was a significant increase in AUROC, but the 
difference was nonetheless numerically small, with a difference between (delta, ) AUROC=0.02; 
p=004 (Figure 1A), and this translates to the need to scan 50 individuals before the information 
conferred in addition to routinely-obtained clinical parameters influences a single diagnostic decision 
(number needed to influence, NNI=50; see Data Management and Analysis section in Supplementary 
Information) .  As anticipated, the discriminatory ability of clinical/laboratory parameters alone with 
respect to diagnostic outcome was diminished in the ACPA-seronegative sub-cohort (AUROC 0.81; 
95% CI =0.77-0.85); the additive contribution of MSUS “synovitis load” was greater than that seen in 
the overall cohort, but remained numerically quite small (AUROC = 0.04; p0.0138; Figure 2B), 
equating to a NNI of 25. Further ROC curve analysis (Figures 2C-D) revealed that the additive 
contribution of the alternative MSUS parameter “scan impression” was greater than that of 
“synovitis load” with respect to diagnostic outcome; this was most evident in the ACPA-seronegative 
sub-cohort, where the AUROC increased by 9% ( AUROC 0.07; p<.0001; Figure 2D), and the NNI 
reduced to 14.  
To examine the possibility that the additive discriminatory value of “scan impression” might be 
susceptible to the experience of the US practitioner, a sensitivity analysis was undertaken in which 
the overall cohort was stratified according to whether MSUS assessment was undertaken by a 
trainer (BT, AGP; n=424) or a trainee (see Supplementary Information; n=407). No significant 
difference was seen in AUROC values derived when the two practitioner groups were compared. 
Following further analyses not presented here, neither were results impacted when considering 
semi-quantitative MSUS parameters as dichotomous (rather than continuous) variables – e.g. 
exploring the predictive utility of the number of joints (out of 7) that exhibited GS and/or PD 
synovitis above pre-defined thresholds, or EMS above and below 60 minutes.  
  
Discussion. 
To our knowledge this is the largest investigation to date of the added utility of MSUS over clinical 
and laboratory parameters in diagnosing SIA in an early arthritis setting. At one level, our “real-
world” findings support previous work suggesting MSUS may be maximally informative for 
diagnostic purposes amongst ACPA-negative individuals[6], confirming this in an unselected SIA 
population. At another our findings inform debate, not only about the choice of scanning algorithm 
to employ when screening SIA patients in time-pressed early arthritis clinics, but also the means by 
which MSUS findings might best be communicated to diagnosticians who may not themselves be 
experts in the technology.  
Several factors underpinned our decision to mandate, as a minimum, assessment of the Backhaus-7 
joint areas[9] in our early arthritis clinic. Paramount amongst these were its coverage (albeit not 
entirely comprehensive) of areas shown to be maximally informative when predicting the 
persistence of very early arthritis[7]; but we felt it was equally important to limit the number of 
mandated joints to permit flexibility within the available time for discretionary assessment of 
additional symptomatic joints. This approach – balancing a defined consistency between all 
assessments with the ability to accommodate case-by-case clinical priorities for reporting purposes, 
is necessarily pragmatic and presents analytical caveats; we nonetheless suggest that it is vindicated 
by our findings. In particular, we observed that the apparent impact of a sonographer’s “scan 
impression” – taking account of all findings (including non-mandated areas) – had an apparently 
more profound impact on diagnosticians' behaviour when forming an impression of PIA than did an 
arguably less subjective measure of “synovitis load” limited to pre-specified areas. Conceivably, 
scope within any MSUS algorithm, for any purpose, to permit discretionary flexibility from skilled 
sonographers when reporting findings to clinical decision-makers may be of pivotal importance: it 
may indeed be an ingredient whose absence underlies hitherto disappointing data to support MSUS 
use in routine clinical practice[18, 19] despite broad expert consensus of its merits[4, 20]. 
Caution must be exercised when interpreting our current analysis. Our data are extracted from 
routine records with no blinding procedures, and MSUS reports contributed to the diagnostic 
assessment. Our interpretation is therefore that the additive contribution of MSUS parameters 
quantified in our study relates to rheumatologists' diagnostic behaviour – and not to diagnosis per 
se. Hence, our data cannot exclude that MSUS findings – and in particular “scan impression” reports 
– might “mislead” diagnosticians into classifying early arthritis patients incorrectly with respect to a 
PIA outcome, engendering ascertainment bias. Although unlikely in our view, future blinded studies 
should address such concerns, whilst formally validating the reliability of “scan impression”. Finally, 
the arguably modest absolute additive contribution of MSUS to diagnostic decision-making in our 
study may in part reflect the relatively low prior probability of PIA outcomes in population(s) 
studied), reinforcing the need to further refine the target population in which to apply this imaging 
modality for diagnostic purposes. 
In conclusion, our data confirm that MSUS findings from a pragmatic 15-minute screen are 
influential upon clinical decision-making in a routine early arthritis setting, particularly for patients 
presenting with ACPA-seronegative SIA. Blinded studies and cost-benefit data amongst this subgroup 
are needed to further define the value of such an approach for broader implementation. 
 
Key messages 
 MSUS may be maximally informative for diagnosing inflammatory arthritis requiring 
DMARDs in ACPA-negative individuals. 
 Sonographers’ global “scan impression” has a greater impact on diagnostic decision-making 
than semi-quantitative scores alone. 
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 Overall cohort 
(n=831) 
PIA 
(n=260) 
Non-PIA 
(n=571) 
P value* 
Clinical / laboratory parameters    
Age 53 (17-95) 58 (20-95) 50 (17-93) <.0001 
Sex (female) 586 (70.5) 162 (19.5) 424 (51.0) 0.0006 
Symptom duration 20 (1-52) 16 (2-52) 24 (1-52) <.0001 
EMS (mins) 30 (0-480) 60 (0-480) 30 (0-120) <.0001 
TJC 5 (0-76) 7 (0-63) 4 (0-76) 0.0642 
SJC 0 (0-33) 2 (0-33) 0 (0-33) <.0001 
GH VAS 50 (0-100) 50 (0-100) 50 (0-100) 0.1742 
CRP 4 (4-278) 8 (4-278) 4 (4-179) <.0001 
ESR 10 (1-132) 21 (2-132) 8 (1-104) <.0001 
RF 171 (20.5) 112 (43.0) 59 (10.3) <.0001 
ACPA 128 (15.4) 114 (43.8) 14 (2.5) <.0001 
Ever smoked 209 (25.2) 80 (30.7) 129 (22.6) 0.0126 
HAQ 0.88 (0-20) 1.13 (0-3) 0.75 (0-20) 0.0083 
MSUS parameters    
GS synovitis load 2 (0-23) 5 (0-23) 1 (0-23) <.0001 
PD synovitis load 0 (0-18) 3 (0-18) 0 (0-15) <.0001 
Scan Impression:     
0 384 (47.0) 32 (12.5) 352 (62.8) <.0001 
1 134 (16.4) 22 (8.6) 112 (19.9) <.0001 
2 299 (36.6) 202 (78.9) 97 (17.3) <.0001 
Table 1. Baseline clinical, laboratory and musculoskeletal ultrasound (MSUS) parameters of overall 
cohort, including univariate analysis amongst patients with persistent inflammatory arthritis (PIA) 
versus non-PIA outcomes. Data presented as median (range) and number (%) for continuous and 
categorical data, respectively.  ACPA, anti-citrullinated peptide antibody (CCP2 assay); EMS, early 
morning stiffness; IQR, inter-quartile range; RF, rheumatoid factor; SD, standard deviation, SxDur, 
symptom duration; T/SJC (max 78), tender/swollen joint count; GH VAS, global health visual 
analogue scale. Baseline MSUS data and corresponding univariate analysis is also presented (see text 
including supplementary methods for definitions); note that despite being 100% predictive for a PIA 
outcome, erosions were scarce and afforded minimal discriminatory value overall, so were excluded 
from further analysis. *Mann-Whitney U/Student's t tests for skewed/normally-distributed 
continuous data respectively; Pearson's χ2 with Fisher’s exact test for dichotomous data. 1Symptom 
duration was censored at 52 weeks if described as longer than this at presentation. 
Figure Legend 
Figure 1. Comparative receiver operator characteristic (ROC) analyses depicting additive value of 
MSUS parameters (blue lines) over clinical parameters alone (red lines) for discriminating PIA versus 
non-PIA diagnoses. The independent additive value of total GS+PD synovitis load (A&B) or scan 
impression (C&D) is shown amongst the entire cohort (n=831; A & C) and the sub-cohort of ACPA-
seronegative individuals (n=703; B&D). Area under (AU) ROC curves (95% confidence intervals) for 
corresponding curves are colour-coded in figures, and p-values denote significant differences 
between AUCs (see methods). See text for further details. 
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Methods Detail. 
Patients and clinical procedures. Consecutive patients ≥16 years of age referred with SIA to the 
NEAC between January 2015 and August 2017 who were naïve to immunomodulatory treatments 
were enrolled. Local guidelines for referral into the clinic include a symptom duration of <12 months 
and at least one of: morning stiffness >30 minutes; symmetrical distribution of arthralgia; positive 
MCP squeeze test[21]. All patients are offered two initial assessment appointments one week apart. 
At the first of these, detailed baseline demographic and clinical parameters are recorded by a nurse, 
MSUS assessment is undertaken and routine blood tests include acute phase markers and 
autoantibodies (rheumatoid factor, RF by nephelemetry and anti-citrullinated peptide antibodies by 
anti-cyclic citrullinated peptide, CCP2 test, Axis Shield). At the subsequent one-week visit patients 
are reviewed by a consultant rheumatologist with access to all of the data and investigation results, 
including up-to-date hand/foot  radiographs; this results in an initial clinical diagnosis being assigned 
to each patient as previously described[22], though with reference to current disease classification 
criteria[23]. For practical purposes we considered a diagnosis of inflammatory arthritis which, in the 
opinion of the consulting rheumatologist, warranted commencement of one or more disease 
modifying anti-rheumatic drugs (DMARDs) during the study period, to be the most clinically relevant 
outcome category when considering the additive contribution of MSUS in clinical decision-making. 
Figure 1A summarises the clinical pathway within which data were collected in the study.  All 
enrolled patients consented to participate in the study, which received a favorable review by the 
Newcastle and North Tyneside Local Research Ethics Committee (Reference 12/NE/0251). 
MSUS Assessment. All patients underwent a MSUS assessment during their first NEAC visit. Our 
pragmatic scanning algorithm took account of local experience and available published reports at 
the study’s inception[3]. We first defined a “minimum MSUS dataset” after the protocol described 
by Backhaus et al[9], mandating that longitudinal dorsal images of the wrist (midline and ulnar-
carpal views), 2nd and 3rd MCPs, 2nd and 3rd PIPs and 2nd and 5th MTPs of the most symptomatic 
hand/foot were recorded for all patients (neutral position; dominant side if equally symptomatic).  
Imaging of additional joint areas was permitted at the discretion of the sonographer and as directed 
by individual patients according to symptoms, but with the total scanning/recoding time limited to 
15 minutes per patient. MSUS findings were recorded on a paper proforma (Figure 1B), capturing 
semi-quantitative scores for greyscale (GS), power Doppler (PD) and erosion domains according to 
consensus definitions[10, 11] on a 0 to 3 scale from the system first suggested by Szudlarek et al 
[24], but adopting the modification of Scheel et al in respect of grey-scale synovitis[25]. GS and PD 
“synovitis load” was calculated for each patient, as the sum of semi-quantitative scores across 7 
joints areas for each domain, yielding summary scores that incorporated only the highest-scoring of 
two probe positions (ulnar and midline) at the wrist to avoid “double-counting”. MSUS parameters 
were also considered as dichotomous variables based on their presence or absence (>2 for GS and 
>1 for PD) at each joint; for simplicity these data are not shown since handling them in this way did 
not impact the outcome of any subsequent analyses. Relevant findings at non-mandated joint areas 
(including tenosynovitis and osteophytes, all recorded as free-text) were also noted. Finally, 
sonographers completed a “scan impression” section, recording a global interpretation of mandated 
and non-mandated scan findings in relation to the presence of inflammatory arthritis (definite, 
possible, absent). Completed proformas were available to consulting rheumatologists during 
subsequent one-week visits. 
Two MSUS systems were in use in the NEAC during the study period; namely the Aplio™ Diagnostic 
Ultrasound System (Toshiba Medical Systems Corporation, Tochigi-Ken, Japan) and the Logiq GE E9™ 
Ultrasound System (General Electric Medical Systems Ltd, Chalfont St Giles, UK), respectively 
employing 12MHz and 15MHz probes for all assessments. A total of 5 rheumatology trainees, as well 
as 2 allied healthcare trainees (one musculoskeletal physiotherapist and one radiographer) carried 
out MSUS assessments during the course of the current study, initially under direct supervision by 
appropriately experienced consultants (BT, AGP); where trainees were deemed competent to 
acquire images/complete proformas without direct supervision, operator identity was recorded to 
facilitate sensitivity analyses, with images regularly reviewed by trainers to ensure consistent semi-
quantitative scoring. Good inter-observer (and excellent intra-observer) agreement of MSUS 
operators in the true-to-life environment described has previously been reported by our group[8, 
26]. Sonographers did not have access to radiographs of hands and feet when making their 
assessments. Data management and analysis. All baseline clinical and demographic data was 
contemporaneously recorded on a bespoke database. Because no added predictive value was 
conferred by considering any of these parameters as dichotomous (E.g. early morning stiffness > or 
<1 hour), all variables were treated as continuous where possible. Baseline semi-quantitative GS, PD 
and erosion scores of individual joints and “scan impression” MSUS data, as well as prospectively 
confirmed diagnostic and DMARD treatment data, were transcribed to the same database from 
clinic proformas after each visit. All analyses were carried out using JMP Pro 13.0 (SAS Institute Inc) 
using methods previously outlined [8]. Briefly, Student's t-tests or Mann-Whitney U tests and 
Pearson's chi-squared were used to describe data, and stepwise logistic regression and the 
construction of receiver operator characteristic (ROC) curves were carried out to determine non-
redundant clinical parameters and their combined discriminatory utility with respect to diagnostic 
outcome. Paired and unpaired comparisons of AU ROCs and their 95% confidence intervals were 
calculated using DeLong’s non-parametric method or approximated from 1000 bootstrap samples.  
Differences in AUROCs were tested using an approximate chi-square test for the difference in AUCs 
relative to their pooled standard errors respectively.  In order to help conceptualise the potential 
clinical relevance of these results, the reciprocal of the difference between compared ROC curves 
was taken as an index of the number of individuals needed for MSUS data to influence one 
diagnostic decision when considered alongside the most discriminatory clinical parameters (denoted 
number needed to influence, NNI). This NNI is averaged across all specificities for a pair of “risk 
metrics” that compare “clinical” with “clinical + MSUS” parameters, acknowledging that in reality it 
depends upon the prevalence of PIA in the population studied[27, 28].  
 
  
Supplementary Figure. 
Figure S1. A. Scheme for patient referral, assessment, diagnosis and follow-up for 831 patients 
described in the observational inception cohort. See text; NEAC: Newcastle Early Arthritis Cohort. B. 
Musculoskeletal (MSK) ultrasound report pro forma employed in routine clinical practice in the NEAC; 
semiquantiative GS and PD scores recorded in the upper table, together with the “Scan Impression” 
(lower portion) were incorporated into analyses as described. C. Distribution of clinical diagnoses 
assigned within the PIA and non-PIA cohorts as defined at the end of the study’s follow-up period. 
RA: rheumatoid arthritis; SpA: spondyloarthritis (includes psoriatic arthritis, ankylosing spondylitis 
and “other spondyloarthritis” categories from Table 1); OA: osteoarthritis; NIA: non-inflammatory 
arthralgia; Crystal: includes gout and pyrophosphate deposition; UA/Other: additional diagnostic 
assignments not otherwise accounted for amongst PIA/non-PIA categories. 
 
 
 
 
  
Supplementary Tables. 
 
Working diagnosis Number (%) assigned diagnosis 
(total = 831) 
Inception  Close of follow-up 
(median 15 months) 
Undifferentiated 75 (9.0)  65 (7.8) 
Rheumatoid arthritis 158 (19.0)  171 (20.6) 
Psoriatic arthritis 56 (6.7)  55 (6.6) 
Ankylosing Spondylitis 6 (0.7)  5 (0.6) 
Other Spondyloarthritis 36 (4.3)  35 (4.2) 
Crystal arthritis 31 (3.7)  30 (3.6) 
Connective tissue disease 12 (1.4)  12 (1.4) 
Non-inflammatory arthralgia 385 (46.3)  382 (46.0) 
Other  72 (8.7)  76 (9.1) 
Table S1. Clinical diagnoses assigned at inception and follow-up for all enrolled patients. 
 
 
Variable Coding if 
categorical 
B SE Wald P value OR (95% CI) 
Complete cohort (n=831) 
ACPA Pos 1    120.71 <.0001 30.77 (16.7-56.7) 
 Neg 0 -1.71 0.16  <.0001 0.03 (0.02-0.06) 
SJC n/a 0.25 0.04 38.98 <.0001 1.29 (1.19-1.39) 
CRP n/a 0.02 0.01 19.88 <.0001 1.02 (1.01-1.03) 
Age n/a 0.02 0.01 8.97 0.0027 1.02 (1.01-1.03) 
Constant n/a -1.41 0.37 14.38 - - 
ACPA-negative sub-cohort (n=703) 
SJC n/a 0.24 0.04 34.70 <.0001 1.27 (1.18-1.38) 
CRP n/a 0.02 0.01 18.73 <.0001 1.02 (1.01-1.03) 
Age n/a 0.02 0.01 9.65 0.0018 1.02 (1.01-1.04) 
Constant n/a -3.19 0.38 68.89 - - 
Table S2. Results of backward stepwise logistic regression analysis to identify independent clinical 
(non-MSUS) predictors of PIA amongst EA clinic attendees. B values are regression coefficients. CI, 
confidence interval; OR, odds ratio; SE, standard error of B. Additional abbreviations as per Table 2. 
Variable Coding if categorical B SE Wald P value OR (95% CI) 
Complete cohort (n=831) 
ACPA Positive      <.0001 32.15 (16.7-61.9) 
 Negative -1.74 0.17 107.61 <.0001 0.03 (0.02-0.06) 
SJC n/a 0.22 0.05 21.76 <.0001 1.24 (1.14-1.36) 
CRP n/a 0.02 0.01 11.30 <.0001 1.02 (1.01-1.03) 
Age n/a 0.00 0.01 0.02 ns 0.99 (0.98-1.01) 
Synovitis Load n/a 0.12 0.02 28.65 <.0001 1.13 (1.08-1.19) 
Constant n/a -0.91 0.41 4.80 - - 
ACPA-negative sub-cohort (n=703) 
SJC n/a 0.21 0.05 19.63 <.0001 1.24 (1.12-1.36) 
CRP n/a 0.02 0.01 10.27 0.0014 1.02 (1.01-1.03) 
Age n/a -0.00 0.01 0.01 ns 1.00 (0.98-1.02) 
Synovitis Load n/a 0.13 0.02 26.28 <.0001 1.13 (1.08-1.19) 
Constant n/a -2.64 0.42 38.87 - - 
Table S3. Results of logistic regression to demonstrate independent predictive value of synovitis load 
(defined as sum of GS and PD scores from 7 mandated joint areas as described in text) with respect 
to PIA diagnosis when considered alongside clinical parameters previously observed to have 
independent discriminatory value. Synovitis Load adds value over and above Clinical Parameters 
especially for ACPA-negative patients. 
 
  
Variable Coding if 
categorical 
B SE Wald P value OR (95% CI) 
Complete cohort (n=831) 
ACPA Positive     <.0001 38.01 (18.7-77.5) 
 Negative -1.82 0.18 100.35 <.0001 0.03 (0.01-0.05) 
SJC n/a 0.14 0.04 11.77 0.0006 1.15 (1.06-1.24) 
CRP n/a 0.04 0.01 7.02 0.0081 1.01 (1.00-1.03) 
Age n/a 0.00 0.01 0.18 ns 1.00 (0.99-1.02) 
Scan Impression None-Possible 
Synovitis[0,1] 
0.84 0.37 5.33 <.0209 0.15 (0.08-0.29) 
 Possible-Definite 
synovitis[1-2] 
1.87 0.32 33.81 <.0001 6.49 (3.5-12.20) 
Constant n/a -1.60 0.41 15.26 - - 
ACPA-negative sub-cohort (n=703) 
SJC n/a 0.14 0.04 11.23 0.0008 1.14 (1.06-1.25) 
CRP n/a 0.01 0.01 5.78 0.0162 1.01 (1.00-1.02) 
Age n/a 0.00 0.01 0.08 ns 1.00 (0.99-1.02) 
Scan Impression None-Possible 
synovitis[0,1] 
1.27 0.41 9.60 0.0020 0.15 (0.08-0.29) 
 Possible-Definite 
synovitis[1-2] 
1.73 0.32 28.88 <.0001 5.68 (3.0-10.63) 
Constant n/a -3.60 0.45 62.73 - - 
Table S4. Results of logistic regression to demonstrate independent predictive value of global scan 
impression (as defined in text) with respect to PIA diagnosis when considered alongside clinical 
parameters previously observed to have independent discriminatory value. Estimates for Scan 
Impression are for the odds of PIA diagnosis comparing a score of 0 (None) to 1 (Possible), and for 1 
(Possible) to 2 (Definite). Scan Impression adds value over and above Clinical Parameter especially for 
ACPA-negative patients. 
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